: Two previous GINECO elderly specific studies in advanced ovarian cancer (AOC) patients highlighted the prognostic value of geriatric covariates for overall survival (OS).
introduction
Ovarian cancer is the leading cause of death from gynaecological cancer in Europe [1] and the Western world [2] . Incidence and mortality increase with age, incidence peaking between 75 and 79 years and mortality between 80 and 84 years. About 50% of cases are diagnosed in women over 65 [1] . Most cases, particularly among elderly patients, are advanced stages (i.e. FIGO stages III-IV) [3] . Age has long been recognized as an independent poor prognostic factor [4] , due in part to suboptimal management and excessive toxicity leading to dose limitations and treatment termination.
In 1997, the French National Group of Investigators for the Study of Ovarian and Breast Cancer (GINECO) initiated a programme evaluating the role of geriatric assessment in patients over 70 years treated with carboplatincyclophosphamide (CC) and standard carboplatin AUC5-paclitaxel (CP) [5, 6] . In a retrospective review of these trials, multivariate analysis of overall survival (OS) revealed a significant negative impact of age and emotional disorders according to the Hospital Anxiety and Depression Scale (HADS) [7] . Stage IV disease and lymphopaenia at study entry were also significantly associated with poor survival. Although patient characteristics favoured the CP group, survival curves were strictly comparable. Paclitaxel (Taxol) use was also an independent poor prognostic factor for survival [hazard ratio (HR) = 2.42, P = 0.001] [6] . While some clinicians consider standard treatment of advanced ovarian cancer (AOC; debulking surgery with six CP cycles) appropriate in elderly patients [8] following proof of feasibility in a selected group [9] , these data nonetheless question the value of combining paclitaxel with platinum in elderly AOC patients.
The current trial extends the GINECO programme, aiming to delineate geriatric covariates to identify vulnerable elderly AOC patients treated with six carboplatin cycles.
patients and methods

study design
This open-label phase II multicentric trial was approved by a national ethics committee and conducted in accordance with the declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent. Data were externally audited by the sponsor. Patients received carboplatin dosed at area under the curve (AUC) 5 mg/ml/min for 30 min every 3 weeks for up to six cycles (see Supplementary Text S1, available at Annals of Oncology online for dose reductions and comedications). The primary end point was to confirm the impact of psychogeriatric covariates on OS. Secondary objectives included assessment of chemotherapy feasibility, chemotherapy-related toxicity, progression-free survival (PFS), tumour response, and the impact of psychogeriatric covariates on treatment tolerance. Chemotherapy feasibility was defined as the completion of six cycles without disease progression, death due to any cause or investigator or patient decision to stop treatment due to chemotherapy-related toxicity.
patient population
Eligible patients were ≥70 years old, with histologically or cytologically proven epithelial FIGO stage III and IV ovarian cancer. Cytology consistent with ovarian cancer was sufficient if associated with both a CA125 rise and a radiological pelvic mass. Patients were ineligible if they had prior chemo-or radiotherapy, planned interval debulking surgery, inadequate hepatic function [transaminases > 3 × upper limit of normal (ULN), total bilirubin > 2 × ULN] , haematological function (neutrophils <1.5 × 10 9 /l, platelets <100 × 10 9 /l) or severe renal insufficiency (creatinine clearance <30 ml/min).
assessments
A pre-inclusion geriatric assessment reviewed the patient's medical charts, nutrition and functionality and an extensive psychocognitive assessment (Supplementary Text S2, available at Annals of Oncology online). Toxicity was assessed throughout using the National Cancer Institute Common Toxicity Criteria, version 3.0.
statistical analyses
Sample size was calculated based on the hypothesis that emotional disorders increase the risk of death at 2 years by threefold (bilateral test) [5, 6] . With an expected risk of death at 24 months of 85%, 105 patients were required with an α error = 5% and β = 10%. Assuming a 5% rate of non-assessable patients, 110 patients were planned. Survival curves were estimated using the Kaplan-Meier method in all enrolled patients (intent-to-treat). Univariate analyses were carried out using log-rank tests. Geriatric variables reaching P < 0.2 and considered clinically relevant were included in a Cox model to identify the optimal combined set of geriatric risk factors, termed geriatric vulnerability parameters. These were used to predict survival by calculating a geriatric vulnerability score (GVS).
The GVS was calculated as follows: survival score = exp(β*N[criteria]), where β is the parameter obtained from the Cox model and N[criteria] is the total number of geriatric vulnerability parameters. Patients were assigned to one of the two subgroups (high-risk and low-risk) using the survival density function. A threshold was determined [receiver operation characteristic (ROC) curves] to discriminate the two subpopulations using the GVS (Supplementary Figures S1 and S2, available at Annals of Oncology online). A univariate survival analysis was carried out using each vulnerability group after adjustment for FIGO stage (IV versus III). The model was internally validated using the integrated Brier score [10] on the whole population and on 100 bootstrap samples. All tests were two-sided. Analyses were carried out using R statistical package (R Foundation for Statistical Computing, Austria) and Splus, version 6.2 (Insightful Corp., WA). 
feasibility and safety
Treatment exposure and safety are summarised in Table 2 . Of the 109 treated patients, 82 received six cycles without severe toxicity or progression [treatment completion rate of 73.9%, 95% confidence interval (95% CI) 65.7%-82.1%]. Of the 27 patients who discontinued early, eight died, three following progression and five due to possibly treatment-related toxicity (septicaemia, two patients; pulmonary embolism, three patients).
tumour response and OS
A total of 98 (88%) patients were assessable for response; 20 patients (18%) had a complete response, 27 (24%) had a partial response, 31 (28%) had stable disease and 20 (18%) had progression. At last follow-up, 75 patients (68%) had died and 13 (12%) were progression-free. The median PFS and OS were 9.2 months (95% CI 7.7-10.6 months) and 17.4 months (95% CI 13.3-21.4 months), respectively.
prognostic factors for OS
Geriatric risk factors associated with decreased survival in univariate analysis and deemed clinically significant were identified (Table 3) . When several covariates were available for the same geriatric dimension, one was selected as best fitting for implementation in the survival model. For nutritional assessment, albuminaemia <35 g/l was chosen over body mass index (BMI) and prognostic inflammatory and nutritional index (PINI) for its good reproducibility and segregation power. For psychological assessment, the HADS score >14 was chosen over the investigator's estimation of emotional disorders as it is more reproducible and has previously been validated [6] . We used two assessment methods for functionality, given that both basal and instrumental activities of daily living (activities of daily living, ADL, and instrumental activities of daily living, IADL, respectively) had a significant impact on survival and are known to be different dimensions of functionality. An equal value was assigned to each geriatric vulnerability criteria: albuminaemia (Table 4) along with a log-rank analysis of survival, the latter confirming good segregation of patients with a GVS of 0-2 versus those with a GVS of 3-5 ( Figure 1 
discussion
We report here the third study in a series of elderly specific trials in ovarian cancer, reflecting GINECO's focus on optimising treatment outcome by exploiting geriatric covariates. A total of 111 patients over the age of 70 were prospectively enrolled. Although eligibility criteria were similar to those of the two original articles Annals of Oncology previous studies, the population in this study had a poorer prognostic factor profile on the basis of geriatric and oncologic parameters (Supplementary Table S1 and Supplementary Text S4, available at Annals of Oncology online). These characteristics are of note given that they conflict with the biases typically observed in elderly patients in clinical trials, which favour fitter patients with fewer comorbid conditions [11] . This study may have been biased towards including more vulnerable patients, partly attributed to investigators' concerns over recruiting fit patients to a trial using carboplatin monotherapy, as well as to the competition of large randomised trials without age limits. At 74% (95% CI 66% to 82%), the treatment completion rate was similar to one of the earlier studies, 76% (95% CI 66% to 85%) and slightly higher than the other at 68% (95% CI 57% to 79%) [5, 6] . Incidence of adverse events, severe adverse events and unplanned hospital admissions were, however, substantial, including 41% of patients with at least one unplanned hospital admission, lasting a median of 7 days. Of the 11 patients who stopped treatment prematurely due to toxicity, 5 died from their complication. The high number of treatment-related deaths with carboplatin monotherapy highlights just how lifethreatening chemotherapy-induced complications can be in a vulnerable elderly population.
With a median of 17.4 months, OS in this trial was lower than in the two earlier trials (21.6 and 25.9 months) [6] . However OS, which we consider a better outcome measure than the response rate or PFS in this population, must be interpreted in light of the poor geriatric risk factor profile.
This study confirmed the effect of psychogeriatric covariates identified in the two earlier trials on survival. In Trial 1, independent prognostic factors identified for OS were depression (P = 0.003), FIGO stage IV (P = 0.007) and more than six comedications daily (P = 0.043). The impact of emotional disorders was confirmed in trial 2, patients with a HADS score of >14 having a significantly increased risk of death (P = 0.015). In a grouped analysis of the two trials (158 patients), independent prognostic factors for poorer OS were increasing age (P = 0.013), baseline symptoms of depression (P < 0.001), FIGO stage IV (P = 0.001) and paclitaxel (Taxol) use (P = 0.025) [12] . In the current study, the effect of emotional disorders was less significant in univariate analysis, but was integrated in the scoring model for its clinical significance and on the basis of a meta-analysis of the three studies which confirms the effect of depression on OS (unpublished data).
Based on the published data, very fit elderly patients, corresponding to the population included in large, randomised trials, can receive current treatment standards; however, little is 
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known about more vulnerable patients. Our study shows that in addition to oncologic risk factors, different treatment strategies should be applied to low-risk versus high-risk elderly patients on the basis of a geriatric assessment, as has been suggested [12] . Future elderly specific prospective trials should focus on vulnerable patients, aided by tools such as the GVS. Among the five GVS risk factors, age over 80 was excluded because it was dependent on other parameters of the geriatric assessment in multivariate analysis. The best-fitting model included two dependent scores evaluating functionality (ADL and IADL), two dependent biological values (albuminaemia and lymphopaenia) and assessment of emotional disorders using the HADS. Other elements of the geriatric assessment were excluded because they did not add information to the fiveitem model in multivariate analysis.
Functionality has been considered a core element in geriatric assessment since being shown to correlate with both OS and survival in healthy condition in the elderly [13, 14] . In a female population, such as in this study, IADL evaluation is rarely compromised by social habits which contribute to heterogeneity between men and women. Furthermore, there is mounting evidence suggesting that IADL correlates strongly with incident dementia and provides insight into cognitive assessment [15, 16] .
Nutrition also plays a key role in geriatric assessment. In the context of cancer, where albuminaemia may be negatively influenced by inflammation, the PINI was also calculated and showed better discriminating power than albuminaemia. Nonetheless, albuminaemia <35 g/l was preferred because of better availability and good reproducibility. In contrast, the BMI had poor discriminating power, likely due to the artefactual impact of ascites.
Lymphopaenia is integral to both the geriatric and the oncologic fields, correlating with morbi-mortality in the former [17] and with the risk of chemo-induced febrile neutropaenia [18] and poorer survival [19, 20] in the latter. In the two earlier GINECO trials, lymphopaenia was associated with decreased survival in a multivariate model (unpublished data).
In summary, with a cut-off score of 3, the GVS can identify two groups with significantly different OS outcomes, treatment completion rates, grade 3-4 non-haematological toxic effects, serious adverse events and unplanned hospital admissions. It provides a valuable tool to identify vulnerable patients in future elderly AOC trials, and will be used in the Elderly Woman Ovarian Cancer GINECO/GCIG trial currently being initiated.
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